Amanote Research
Register
Sign In
Incidence and Risk of Hematologic Toxicities in Cancer Patients Treated With Regorafenib
Oncotarget
- United States
doi 10.18632/oncotarget.21217
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
September 24, 2017
Authors
Bin Zhao
Hong Zhao
Publisher
Impact Journals, LLC
Related search
Correction: Incidence and Risk of Hematologic Toxicities in Cancer Patients Treated With Regorafenib
Oncotarget
Oncology
Risk of Severe Hematologic Toxicities in Cancer Patients Treated With PARP Inhibitors: A Meta-Analysis of Randomized Controlled Trials
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Incidence and Risk of Severe Neutropenia in Advanced Cancer Patients Treated With Cetuximab
Drugs in R and D
Pharmacology
Factors Predicting Acute Hematologic Toxicities in Cervical Cancer Treated With Postoperative Intensity-Modulated Radiation Therapy and Concurrent Nedaplatin
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
Paclitaxel-Carboplatin Chemotherapy Induced Hematologic Toxicities Among Epithelial Ovarian Cancer Patients
Universa Medicina
P3.01-100 Risk of Gastrointestinal and Hepatic Toxicities in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Osimertinib
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Real-World Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib
Clinical Colorectal Cancer
Oncology
Gastroenterology
Incidence and Relative Risk of Peripheral Neuropathy in Cancer Patients Treated With Eribulin: A Meta-Analysis
Oncotarget
Oncology
Real‐World Adherence in Patients With Metastatic Colorectal Cancer Treated With Trifluridine Plus Tipiracil or Regorafenib
Oncologist
Cancer Research
Medicine
Oncology
